Stockreport

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Disc Medicine, Inc.  (IRON) 
PDF Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketin [Read more]